^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
EBTATE
i
Other names: EBTATE, 177Lu-DOTA-EB-TATE, 177Lu-DOTA-EB-TATE 1 , 177Lu-DOTA-EB-TATE 2, 177Lu-DOTA-EB-TATE 3, 177Lu-EBTATE
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Molecular Targeting Tech, National Institutes of Health
Drug class:
Beta radiation emitter, SSTR2 modulator
Related drugs:
6ms
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (clinicaltrials.gov)
P1/2, N=18, Not yet recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
New P1/2 trial
|
EBTATE
8ms
Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study. (PubMed, Acta Pharm Sin B)
Previous studies have shown that an SSTR2 agonist combined with albumin binding moiety Evans blue (denoted as 177Lu-EB-TATE) is characterized by a higher tumor uptake and residence time in preclinical models and in patients with metastatic NETs. Preliminary PRRT efficacy results showed an 83% disease control rate and a 42% overall response rate after two 177Lu-LNC1010 treatment cycles. These encouraging findings warrant further investigations through multicenter, prospective, and randomized controlled trials.
P1 data • Preclinical • Journal
|
SSTR2 (Somatostatin Receptor 2)
|
177Lu-LNC1010 • EBTATE
1year
Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors. (PubMed, Eur J Nucl Med Mol Imaging)
[225Ac]Ac-EBTATE is safe and effective against SCLC and pan-NET and therefore warrants clinical investigation.
Preclinical • Journal
|
SSTR2 (Somatostatin Receptor 2)
|
SSTR2 expression • SSTR2 overexpression • SSTR2 underexpression
|
EBTATE
over1year
Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors. (PubMed, J Nucl Med)
The antitumor efficacy of [67Cu]Cu-EB-TATE is comparable to that of [177Lu]Lu-EB-TATE, with [67Cu]Cu-EB-TATE being slightly more effective than [177Lu]Lu-EB-TATE for complete remission of small tumors. [67Cu]Cu-EB-TATE therefore warrants clinical development.
Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR2 positive
|
EBTATE
over1year
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors (clinicaltrials.gov)
P1, N=9, Recruiting, Molecular Targeting Technologies, Inc. | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
SSTR (Somatostatin Receptor)
|
SSTR Expression
|
EBTATE
over3years
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, Peking Union Medical College Hospital | Unknown status --> Recruiting | N=20 --> 60 | Trial completion date: Dec 2019 --> May 2023 | Trial primary completion date: Dec 2019 --> Dec 2022
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
|
SSTR (Somatostatin Receptor)
|
SSTR Expression
|
Lutathera (lutetium Lu 177 dotatate) • EBTATE • Solucin (177Lu-edotreotide)
over3years
177Lu-DOTA-EB-TATE in Untreated (Naïve) Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors (clinicaltrials.gov)
P1, N=9, Recruiting, Molecular Targeting Technologies, Inc.
New P1 trial
|
SSTR (Somatostatin Receptor)
|
SSTR Expression
|
EBTATE
Share via
